Whole-genome sequencing and newborn screening

How newborn screening works now

In the UK, newborn screening currently centres on the blood-spot, or heel-prick, test, usually done when a baby is about five days old. A few drops of blood are collected onto a card and tested for a small number of rare but serious conditions where early treatment makes a big difference — for example certain inherited metabolic disorders, sickle cell disease, cystic fibrosis and congenital hypothyroidism. The list is chosen carefully so that screening only looks for conditions that can be reliably detected and where acting early clearly helps the baby. Babies are also offered newborn physical checks and hearing screening. This established programme has a strong track record of catching treatable conditions before they cause harm.

What whole-genome sequencing is

Whole-genome sequencing means reading almost all of a person's DNA — the full set of genetic instructions found in nearly every cell. Instead of testing for a handful of specific conditions, it can, in principle, examine thousands of genes at once. The technology has become dramatically faster and cheaper over the past two decades, so what once took years and huge sums can now be done far more quickly. In babies, a sample can be taken from the same kind of blood spot. Researchers are interested in whether sequencing could pick up many more rare genetic conditions early, especially ones with treatments that work best when started before symptoms appear. It is a powerful tool, but a very different one from targeted screening.

The promise for rare disease

Rare genetic conditions are individually uncommon but, taken together, affect a significant number of children, and families often endure a long and distressing search for a diagnosis. Whole-genome sequencing at birth could, in theory, shorten or avoid that journey by identifying certain conditions before symptoms begin, allowing treatment or monitoring to start early — sometimes preventing serious harm. For conditions with effective early treatments, this could be genuinely life-changing. Research studies, including large UK programmes, are testing how well sequencing performs in newborns, which conditions it should look for, and whether earlier diagnosis truly improves outcomes. The aim is to add value to the existing programme, not to replace careful judgement about what is worth screening for.

The ethical questions

Reading a baby's whole genome raises real dilemmas. It may reveal information the family did not ask for, such as risks of conditions that appear only in adulthood or that have no treatment, which can cause worry without offering a clear way to help. There are questions about consent — a baby cannot choose, and parents decide on their behalf about information the child might prefer to control later. Uncertain findings, where the meaning of a genetic change is unclear, can cause anxiety and lead to more tests. Privacy and how genetic data is stored, shared and protected are important, as is fairness, since genetic databases have historically underrepresented some groups. These issues are why any expansion is being explored carefully and gradually.

Where this is heading

Whole-genome sequencing in newborns is being studied rather than rolled out as routine care, with research assessing benefits, harms, accuracy and public views before any wider adoption. Careful choices are needed about which conditions to include — ideally those that are serious, can be reliably detected, and have treatments that work better when started early. Good information and support for parents, clear consent, and strong safeguards for genetic data all matter. The existing blood-spot programme continues to serve babies well in the meantime. If sequencing is eventually offered more widely, it is likely to be alongside, and guided by, the same principle that has always underpinned screening: only look for what genuinely helps the child.